Biodegradable Polymer Conjugates For Targeted Cancer Drug Delivery

A novel biodegradable polymer conjugate technology enabling precise and effective delivery of PD-L1 inhibitors and anti-cancer agents for improved cancer treatment.

Traditional chemotherapies have challenges including poor targeting and systemic toxicity due to uncontrolled drug release that can cause adverse side effects. These challenges can also result in insufficient delivery of chemotherapies such as PD-L1 inhibitors at tumor sites.

This technology features biodegradable drug delivery conjugates composed of two polymeric segments linked by a cleavable peptide linker, where each segment is covalently bonded to at least one PD-L1 inhibitor or anti-cancer agent. The design allows controlled release triggered by enzymatic or pH changes, enhancing the delivery and efficacy of therapeutic agents in treating a broad range of cancers. This method may support various administration schedules and target solid tumors as well as hematologic malignancies.

Pre-Clinical Validation

• Targeted and controlled release of anti-cancer drugs and PD-L1 inhibitors via cleavable peptide linkers
• Biodegradable polymer backbone minimizing long-term toxicity
• Potential compatibility with multiple cancer types
• Adjustable molecular weight and valence for enhanced pharmacokinetics and tumor accumulation

Publication Number: WO 2018/031521 A1
Patent Title: POLYMERIC DRUG DELIVERY CONJUGATES AND METHODS OF MAKING AND USING THEREOF
Jurisdiction/Country: United States
Application Type: Non-Provisional

Jason Young
(801) 587-0519
jason.r.young@utah.edu